Targeting the transferrin receptor to develop erythropoietin for Alzheimer's disease
Rachita K. Sumbria
Department of Biopharmaceutical Sciences,School of Pharmacy and Health Sciences,Keck Graduate Institute,Claremont;Department of Neurology,University of California,Irvine,CA,USA
摘要：Alzheimer's disease (AD) is the sixth leading cause of death in the United States with approximately 5.8 million Americans currently living with AD. Due to the lack of a disease modifying treatment for AD and the aging baby boomer generation, this number is pro-jected to grow to 13.8 million by 2050 (Gaugler et al., 2019). Amy-loid-beta (Aβ) plaque accumulation, one of the major pathological hallmarks of AD, can begin > 20 years before clinical symptoms of AD. By the time AD is clinically diagnosed, neuronal loss and neu-ropathological lesions (Aβ plaques and tau tangles) have already occurred in many brain regions (Gaugler et al., 2019). AD demen-tia correlates highly with neuronal loss, and therefore, reduction of neuropathological lesions in the AD brain at the time of clinical diagnosis alone cannot reverse AD dementia. We propose that a therapy that combines a reduction of neuropathological lesions of AD along with neuronal repair and neurogenesis may be required to treat AD dementia.
机标关键词：
论文发表日期：2020-12-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 2251-2252 )